A phase 1 trial of adoptive transfer of vaccine-primed autologous circulating T cells in ovarian cancer.
Sara BobisseValentina BianchiJanos L TanyiApostolos SarivalasisEdoardo MissiagliaRémy PétremandFabrizio BenedettiDrew A TorigianRaphaël GenoletDavid BarrasAlexandra MichelSpyridon A MastroyannisEmese ZsirosDenarda Dangaj LanitiZoi TsourtiBrian J StevensonChristian IseliBruce L LevineDaniel E SpeiserDavid GfellerMichal Bassani-SternbergDaniel J PowellCarl H JuneUrania DafniLana Elias KandalaftAlexandre HarariSergio A QuezadaPublished in: Nature cancer (2023)
We have previously shown that vaccination with tumor-pulsed dendritic cells amplifies neoantigen recognition in ovarian cancer. Here, in a phase 1 clinical study ( NCT01312376 /UPCC26810) including 19 patients, we show that such responses are further reinvigorated by subsequent adoptive transfer of vaccine-primed, ex vivo-expanded autologous peripheral blood T cells. The treatment is safe, and epitope spreading with novel neopeptide reactivities was observed after cell infusion in patients who experienced clinical benefit, suggesting reinvigoration of tumor-sculpting immunity.